Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy & Safety of Piroxicam Plus Counterirritant Gel Compared With Other Topical NSAIDs in Managing Musculoskeletal Pain
NCT07475663Phase 3Completed
- Sponsor
- Taisho Pharmaceutical Indonesia
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Musculoskeletal pain, osteoarthritis (OA), Ankle sprain and 4 more (3 arms), sponsored by Taisho Pharmaceutical Indonesia. Primary endpoint: Brief Pain Inventory score reduction at 4 months. Started Nov 2025; status: completed.
02
Conditions
Musculoskeletal painosteoarthritis (OA)Ankle sprainPatellar Tendinitis (PT)Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on NCT07475663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475663.